Inhibrx Biosciences, Inc. (INBX) — 8-K Filings

8-K Filings (10)

• Inhibrx Biosciences Files 8-K on Dec 16, 2025 — Dec 16, 2025 Risk: low
  Inhibrx Biosciences, Inc. filed an 8-K on December 16, 2025, to report on various events. The filing includes information on financial statements and exhibits,
• Inhibrx Biosciences Files 8-K — Oct 23, 2025 Risk: low
  On October 23, 2025, Inhibrx Biosciences, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures, other events, and financial stateme
• Inhibrx Biosciences Files 8-K on Security Holder Vote — May 28, 2025 Risk: low
  On May 28, 2025, Inhibrx Biosciences, Inc. filed an 8-K report to announce the submission of matters to a vote of its security holders. The company, formerly kn
• Inhibrx Biosciences Announces Director and Officer Changes — Apr 1, 2025 Risk: medium
  On March 31, 2025, Inhibrx Biosciences, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing
• Inhibrx Biosciences Files 8-K Report — Jan 21, 2025 Risk: low
  On January 21, 2025, Inhibrx Biosciences, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Financia
• Inhibrx Biosciences Files 8-K with Material Agreements — Jan 13, 2025 Risk: medium
  On January 13, 2025, Inhibrx Biosciences, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported o
• Inhibrx Biosciences Relocates Principal Executive Offices — Nov 4, 2024 Risk: low
  On November 4, 2024, Inhibrx Biosciences, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 11025 N. Torre
• Inhibrx Biosciences Files 8-K — Jun 17, 2024 Risk: low
  On June 17, 2024, Inhibrx Biosciences, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. Ther
• Inhibrx Biosciences Enters Material Agreement, Completes Spin-Off — May 30, 2024 Risk: medium
  On May 29, 2024, Inhibrx Biosciences, Inc. entered into a material definitive agreement related to its spin-off from 03 Life Sciences. This event also involves
• Inhibrx Biosciences Files 8-K Report — May 24, 2024 Risk: low
  On May 24, 2024, Inhibrx Biosciences, Inc. filed an 8-K report. The filing primarily concerns a Regulation FD Disclosure and Financial Statements and Exhibits.

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX